CONFIDENTIAL Amendment #1 to the Letter of Agreement between SmithKline Beecham Corporation and Quest Diagnostics Incorporated

EX-10.1 2 c53221_ex10-1.htm c53221_ex10-1.htm

Exhibit 10.1

CONFIDENTIAL

Amendment #1 to the
Letter of Agreement between
SmithKline Beecham Corporation and
Quest Diagnostics Incorporated

Effective March 31, 2008

   
1.        

The purpose of this Amendment #1 to the Letter of Agreement effective January 1, 2008 between SmithKline Beecham Corporation d/b/a GlaxoSmithKline and Quest Diagnostics Incorporated (hereinafter the “LOA”) is to extend the term referenced in section 2 of the LOA to the earlier of (i) May 31, 2008, or (ii) the full execution of a new comprehensive Global Clinical Trials Agreement.
 
2.

All other terms and conditions of the LOA shall remain in full force and effect.
 
3.

The parties hereto agree to this Amendment #1 to the LOA by their authorized signatures below.
 

SMITHKLINE BEECHAM CORPORATION   QUEST DIAGNOSTICS INCORPORATED  
       
       
       
Paula M. Russella   Daniel P. Megronigle  
Sourcing Group Manager   Executive Director, Sales & Marketing  
       
       
Date   Date  

 

 

Letter of Agreement, Amendment #1

Page 1 of 1